On day 2 of the Association of Community Cancer Centers (ACCC)'s 45th Annual Meeting & Cancer Center Business Summit, we spoke with Ali McBride, PharmD, MS, BCPS, BCOP, clinical coordinator of hematology/oncology in the Department of Pharmacy at The University of Arizona Cancer Center, and James Hamrick, MD, senior medical director at Flatiron Health.
Today-
We are on site in Washington, DC, for day 2 of the Association of Community Cancer Centers’ Annual Meeting and Cancer Center Business Summit!
We will be recapping some of the top news presented each day during the meeting—and soon we’ll speak with James Hamrick, MD, senior medical director of Flatiron Health, and Ali McBride, PharmD, MS, BCPS, BCOP, incoming president of ACCC.
Welcome to AJMC® On Location! I’m Jaime Rosenberg.
The second day of the meeting focused on technology in healthcare and the digital health revolution. There was a session on likely innovations in health IT over the next 18 years based on insights from leaders in government, academia, and industry. In addition, there was a panel discussion on how wearables are generating patient-reported outcomes and empowering providers to be able to better manage symptoms and improve resource utilization.
Read about these stories and watch additional interviews from the meeting at AJMC.com.
That’s all from the ACCC Annual Meeting and Cancer Center Business Summit. Join us again April 4-5, when we will be reporting on site at the Community Oncology Alliance’s Community Oncology Conference being held in Orlando, Florida.
Thank you for watching AJMC® News Network! I’m Jaime Rosenberg.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More